You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells

Article metrics

Article menu
Immune cell therapies and immune cell engineering
Original research
High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells

 

Online download statistics by month:

Online download statistics by month: February 2022 to February 2026

AbstractFullPdf
Feb 202212301275417
Mar 2022334365152
Apr 202223725889
May 202219519788
Jun 202217819047
Jul 202216817060
Aug 202221121591
Sep 202218219169
Oct 202218619680
Nov 202215215251
Dec 202214014255
Jan 202313213241
Feb 202314114344
Mar 202316416599
Apr 202312913267
May 202312312541
Jun 202312812845
Jul 202310210246
Aug 2023747431
Sep 2023939446
Oct 2023939534
Nov 202310912161
Dec 202310614988
Jan 202410412458
Feb 202411413159
Mar 2024126140102
Apr 202411311648
May 202410312361
Jun 2024888930
Jul 202411011549
Aug 20248587123
Sep 2024757641
Oct 2024838434
Nov 2024989939
Dec 202413113457
Jan 202511311558
Feb 2025646537
Mar 2025989869
Apr 2025909046
May 2025575827
Jun 2025535322
Jul 2025110
Feb 2026110
Total631466102802